AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12870566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10887306 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microgram, 2 puffs 4 times daily)
Number of subjects: 14
Study 10887306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8656680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednimustine/mitoxantrone (PmM)
Number of subjects: 246
Study 8656680 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine, prednisone (COP)
Number of subjects: 246
Study 14621753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential course of 14 days conventional immunosuppression (ALG, azathioprine, steroids) followed by cyclosporine and steroids
Number of subjects: 114
Study 14621753 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression for 2 days followed by cyclosporine and steroids
Number of subjects: 114
Study 4081351 — intervention group
Group type: EXPERIMENTAL
Intervention: Puncture of thoracic pain points (n = 8)
Number of subjects: 17
Study 4081351 — intervention group
Group type: COMPARATOR
Intervention: Puncture in extrathoracic zones (lower limbs) (n = 9)
Number of subjects: 17
Study 4081351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (thoracic and extrathoracic puncture)
Number of subjects: 17
Study 29308844 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Contrast Training (CCT)
Number of subjects: 22
Study 29308844 — intervention group
Group type: COMPARATOR
Intervention: Traditional Strength Training (TST)
Number of subjects: 22
Study 28952459 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 72
Study 28952459 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 72
Study 27036555 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) lansoprazole
Number of subjects: 332
Study 27036555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 25291127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius LS01 with S. thermophilus ST10 and tara gum (probiotic group)
Number of subjects: 25
Study 25291127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study 22604276 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telemonitored cardiac rehabilitation (HTCR)
Number of subjects: 75
Study 22604276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-event-Halter ECG facility
Number of subjects: 75
Study 22604276 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic ECG recordings
Number of subjects: 75
Study 19910293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary BMC
Number of subjects: 78
Study 19910293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 18056516 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer navigation
Number of subjects: 45
Study 18056516 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 45
Study 18056516 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of results
Number of subjects: 45
Study 16082736 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment (peginterferon monotherapy for 48 weeks or shorter combination therapy for 24 weeks for RVR; triple therapy with histamine for 48 weeks or prolonged combination therapy for 72 weeks for SPR; triple therapy for FPR; high-dose peginterferon (360 microg/week) plus ribavirin for NUR)
Number of subjects: 270
Study 16082736 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (peginterferon alfa-2a 180 microg/week and ribavirin 1000-1200 mg/day)
Number of subjects: 270
Study 16082736 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (1 mg/day) in addition to peginterferon and ribavirin
Number of subjects: 270
Study 16082736 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose peginterferon (360 microg/week) plus ribavirin
Number of subjects: 270
Study 11374121 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR) for 15 min at 50% of VO2max after 60 min of uphill running at 83% of VO2max
Number of subjects: 13
Study 11374121 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 13
Study 11374121 — intervention group
Group type: COMPARATOR
Intervention: Complete Rest (RR)
Number of subjects: 13
Study 9042563 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture
Number of subjects: 0
Study 9042563 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 0
Study 9042563 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 0
Study 7952988 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chlorpromazine (600 mg daily) and electroconvulsive therapy (ECT)
Number of subjects: 15
Study 7952988 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 15
Study 3555510 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 10 mg/week, orally
Number of subjects: 42
Study 3555510 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA), 100 mg/day, orally
Number of subjects: 42
Study 3555510 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 42
Study 3555510 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 42
Study 3555510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 42
Study 2294126 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) at a dose of 1 IU/kg.week
Number of subjects: 40
Study 2294126 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) at a dose of 1 IU/kg.week + 25 ng/kg.day ethinyl estradiol (E2)
Number of subjects: 40
Study 2294126 — intervention group
Group type: COMPARATOR
Intervention: Control group (hGH alone)
Number of subjects: 40
Study 1100683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine-containing gel used once a day for 4 weeks
Number of subjects: 36
Study 1100683 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel used during control period for 4 weeks
Number of subjects: 36
Study 1100683 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized oral hygiene instruction for 12 subjects
Number of subjects: 36
Study 31940591 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo Treg depletion (IVTRD) with basiliximab 20 mg IV on day +1 post-ASCT
Number of subjects: 15
Study 31940591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo Treg depletion (EVTRD) using anti-CD25 microbeads and CliniMACS device
Number of subjects: 15
Study 31940591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Treg depletion)
Number of subjects: 15
Study 31446628 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Illness Perception Questionnaire (Brief‐IPQ)
Number of subjects: 571
Study 29871195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin (ITG), 1 ml of gentamicin sulfate (40 g/L) buffered with 0.5 ml of sodium bicarbonate, administered weekly for 2 times
Number of subjects: 70
Study 29871195 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD), 5 mg for the first two days, then weekly for 4 weeks
Number of subjects: 70
Study 29871195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin (ITG)
Number of subjects: 70
Study 29871195 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD)
Number of subjects: 70
Study 26013113 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal drug combination (Sinupret® extract Dragees) - daily dosage 3 × 160 mg
Number of subjects: 386
Study 26013113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 26013113 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal drug combination (Sinupret® extract Dragees)
Number of subjects: 386
Study 23812875 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegSimple (once-daily insulin degludec with simple titration algorithm)
Number of subjects: 222
Study 23812875 — intervention group
Group type: COMPARATOR
Intervention: IDegStep-wise (once-daily insulin degludec with step-wise titration algorithm)
Number of subjects: 222
Study 23812875 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegSimple
Number of subjects: 222
Study 23812875 — intervention group
Group type: COMPARATOR
Intervention: IDegStep-wise
Number of subjects: 222
Study 22303704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin calcium (LMWHC) combined with Yinxing Damo Injection (YDI)
Number of subjects: 62
Study 22303704 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin calcium (LMWHC)
Number of subjects: 62
Study 22303704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin calcium (LMWHC) combined with YDI
Number of subjects: 62
Study 19338692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Family Partnership (NFP) home visitation services starting in pregnancy until age 2; n = 93.
Number of subjects: 237
Study 19338692 — intervention group
Group type: COMPARATOR
Intervention: Comparison services; n = 144.
Number of subjects: 237
Study 16767851 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and brief intervention
Number of subjects: 0
Study 16767851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0
Study 15065979 — intervention group
Group type: EXPERIMENTAL
Intervention: Postidentification feedback after target-absent lineups
Number of subjects: 0
Study 15065979 — intervention group
Group type: EXPERIMENTAL
Intervention: Postidentification feedback after target-present lineups
Number of subjects: 0
Study 15065979 — intervention group
Group type: EXPERIMENTAL
Intervention: Postidentification feedback
Number of subjects: 0
Study 15065979 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence measure reference point (retrospective vs. current confidence)
Number of subjects: 0
Study 11134468 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC/ZDV
Number of subjects: 205
Study 11134468 — intervention group
Group type: COMPARATOR
Intervention: 3TC/ZDV
Number of subjects: 205
Study 9402542 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoaraiosis in centrum semiovale group
Number of subjects: 30
Study 9402542 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular leukoaraiosis group
Number of subjects: 30
Study 9402542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8481170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 58
Study 8481170 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 58
Study 2963644 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg (0.04 mg) controlled dosage aerosol
Number of subjects: 107
Study 2963644 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg ipratropium bromide (ITB)
Number of subjects: 107
Study 2963644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doses between 0.25 mg and 0.5 mg ITB
Number of subjects: 107
Study 30224391 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group-based cognitive remediation therapy (CRT)
Number of subjects: 260
Study 30224391 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 260
Study 26259833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements
Number of subjects: 358
Study 24671165 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐CHESS smartphone application (treatment as usual plus A‐CHESS)
Number of subjects: 349
Study 24671165 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 349
Study 23764181 — intervention group
Group type: COMPARATOR
Intervention: 12 months of trastuzumab (control group)
Number of subjects: 3384
Study 23764181 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of trastuzumab (experimental group)
Number of subjects: 3384
Study 19887503 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 to 16 mg daily)
Number of subjects: 502
Study 19887503 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 502
Study 19887503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 18929814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine plus Everolimus (group CE, n = 32)
Number of subjects: 108
Study 18929814 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine plus Mycophenolate Mofetil (MMF) (group CM, n = 24)
Number of subjects: 108
Study 18929814 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus plus Mycophenolate Mofetil (MMF) (group TM, n = 25)
Number of subjects: 108
Study 18929814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine plus Everolimus (group CE)
Number of subjects: 108
Study 18929814 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine plus Mycophenolate Mofetil (MMF) (group CM)
Number of subjects: 108
Study 18929814 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus plus Mycophenolate Mofetil (MMF) (group TM)
Number of subjects: 108
Study 17407945 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate drain release (Group A)
Number of subjects: 100
Study 17407945 — intervention group
Group type: COMPARATOR
Intervention: Delayed drain release (Group B)
Number of subjects: 100
Study 12846705 — intervention group
Group type: COMPARATOR
Intervention: Desflurane 0.5 MAC
Number of subjects: 20
Study 12846705 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 1.0 MAC
Number of subjects: 20
Study 12846705 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 1.5 MAC
Number of subjects: 20
Study 11474870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 80 micrograms
Number of subjects: 9
Study 11474870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9519495 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 246
Study 9519495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 8214699 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 67
Study 8214699 — intervention group
Group type: EXPERIMENTAL
Intervention: thiopental
Number of subjects: 67
Study 8214699 — intervention group
Group type: EXPERIMENTAL
Intervention: methohexital
Number of subjects: 67
Study 8214699 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 67
Study 3117447 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 6
Study 3117447 — intervention group
Group type: EXPERIMENTAL
Intervention: GH releasing factor (GRF)
Number of subjects: 6
Study 3117447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of insulin and GRF
Number of subjects: 6
Study 3117447 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycaemia
Number of subjects: 6
Study 31952985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatremia at discharge
Number of subjects: 708
Study 31952985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatremia at discharge among patients who were hyponatremic on admission
Number of subjects: 708
Study 31952985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatremia on admission but normalized serum sodium levels at discharge
Number of subjects: 708
Study 31420292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone at home
Number of subjects: 180
Study 31420292 — intervention group
Group type: COMPARATOR
Intervention: Intravenous flucloxacillin in hospital
Number of subjects: 180
Study 29131084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 75
Study 29131084 — intervention group
Group type: COMPARATOR
Intervention: Intensive Relaxation Training (RT)
Number of subjects: 75
Study 25837194 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural injection (PN)
Number of subjects: 78
Study 25837194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single perivascular infiltration (PV1)
Number of subjects: 78
Study 25837194 — intervention group
Group type: EXPERIMENTAL
Intervention: Double perivascular infiltration (PV2)
Number of subjects: 78
Study 25837194 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 78
Study 24165382 — intervention group
Group type: EXPERIMENTAL
Intervention: LT vaccine
Number of subjects: 603
Study 24165382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 21574174 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg/day vitamin K2
Number of subjects: 548
Study 21574174 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/day vitamin K2
Number of subjects: 548
Study 21574174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 19794995 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted autogenic training
Number of subjects: 53
Study 19794995 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group
Number of subjects: 53
Study 16855947 — intervention group
Group type: EXPERIMENTAL
Intervention: Full correction of refractive errors (glasses prescribed for myopia, astigmatism, hyperopia > +0.5 dpt)
Number of subjects: 58
Study 12973229 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (20 U)
Number of subjects: 273
Study 12973229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 10703633 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% strontium nitrate in 70% glycolic acid (pH=0.6)
Number of subjects: 8
Study 10703633 — intervention group
Group type: COMPARATOR
Intervention: 70% glycolic acid (pH=0.6)
Number of subjects: 8
Study 8990771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 500 mg/kg
Number of subjects: 141
Study 8990771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 141
Study 1467095 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural infusion of 0.15% bupivacaine with 0.01% diamorphine
Number of subjects: 0
Study 1467095 — intervention group
Group type: COMPARATOR
Intervention: Extradural bolus diamorphine 3.6 mg
Number of subjects: 0
Study 1467095 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled i.v. administration of diamorphine at a maximum rate of 1 mg per 5 min
Number of subjects: 0
Study 6379507 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine brain gangliosides, 40 mg daily intramuscular injections for 6 months
Number of subjects: 40
Study 6379507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30409751 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention for weight management
Number of subjects: 40
Study 30409751 — intervention group
Group type: COMPARATOR
Intervention: Control group (general health information)
Number of subjects: 40
Study 29320927 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcuff tracheal tubes
Number of subjects: 80
Study 29320927 — intervention group
Group type: COMPARATOR
Intervention: Conventional uncuffed tubes
Number of subjects: 80
Study 26854833 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized (problem-adapted) written recommendations
Number of subjects: 337
Study 26854833 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 337
Study 24424425 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400mg/d)
Number of subjects: 118
Study 24424425 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa (800/200mg/d)
Number of subjects: 118
Study 24424425 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg/d)
Number of subjects: 118
Study 24424425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 22242600 — intervention group
Group type: COMPARATOR
Intervention: Direct composite resin (positive control)
Number of subjects: 100
Study 22242600 — intervention group
Group type: COMPARATOR
Intervention: Partial coverage with composite resin
Number of subjects: 100
Study 22242600 — intervention group
Group type: COMPARATOR
Intervention: Conventional full coverage with composite resin
Number of subjects: 100
Study 22242600 — intervention group
Group type: COMPARATOR
Intervention: Modified full coverage with composite resin
Number of subjects: 100
Study 22242600 — intervention group
Group type: COMPARATOR
Intervention: Untreated (negative control)
Number of subjects: 100
Study 22242600 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 20953063 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training on a cycloergometer, 3 times a week, at 70‐80% of the maximum tolerated heart rate (HR) (training group, n=60)
Number of subjects: 120
Study 20953063 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=60)
Number of subjects: 120
Study 17432998 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized recommendations to reduce exposure to allergens (dust mite, pets, food allergens) and passive smoking
Number of subjects: 222
Study 17432998 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks longer breastfeeding
Number of subjects: 222
Study 16372814 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-cyclophosphamide (D/C) pulse therapy
Number of subjects: 22
Study 16372814 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone-azathioprine (M/A) therapy
Number of subjects: 22
Study 12063318 — intervention group
Group type: EXPERIMENTAL
Intervention: REM sleep
Number of subjects: 32
Study 12063318 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-REM sleep
Number of subjects: 32
Study 12063318 — intervention group
Group type: EXPERIMENTAL
Intervention: Short- and intermediate-term intervals
Number of subjects: 32
Study 12063318 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups during REM sleep
Number of subjects: 32
Study 10215093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reaction-time tasks, semantic memory task, memory comparison task, mental rotation task, mirror reading task
Number of subjects: 12
Study 10215093 — intervention group
Group type: COMPARATOR
Intervention: Cognitive reaction-time tasks with opportunities for procedural learning
Number of subjects: 12